Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study-Reference-Cited by-同舟云学术

Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study

Published:2014-11-11 Issue:2 Volume:35 Page:448-454
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Berg Thomas¹,Andreone Pietro²,Pol Stanislas³,Roberts Stuart⁴,Younossi Zobair⁵,Diago Moises⁶,Lawitz Eric J.⁷,Focaccia Roberto⁸,Foster Graham R.⁹,Horban Andrzej¹⁰,Lonjon-Domanec Isabelle¹¹,DeMasi Ralph¹²,Picchio Gaston¹²,Luo Donghan¹²,De Meyer Sandra¹³,Zeuzem Stefan¹⁴

Affiliation:

1. Universitätsklinikum Leipzig; Sektion Hepatologie; Klinik für Gastroenterologie und Rheumatologie; Leipzig Germany

2. Dipartimento di Scienze Mediche e Chirurgiche; Università di Bologna; Bologna Italy

3. Université Paris Descartes; INSERM Unité 1016; and Assistance Publique-Hôpitaux de Paris; Cochin Hospital; Paris France

4. Department of Gastroenterology; Alfred Hospital; Melbourne Victoria Australia

5. Center for Liver Diseases and Department of Medicine; Inova Fairfax Hospital; Falls Church Virginia USA

6. Hospital General de Valencia; Valencia Spain

7. Alamo Medical Research; San Antonio Texas USA

8. Emilio Ribas Institute of Infectious Diseases; São Paulo Brazil

9. Queen Marys University of London; Institute of Cell and Molecular Science; London UK

10. Medical University of Warsaw; Wolska Warsaw Poland

11. Janssen; Paris France

12. Janssen Research and Development LLC; Titusville New Jersey USA

13. Janssen Infectious Diseases BVBA; Beerse Belgium

14. Johann Wolfgang Goethe University Medical Center; Frankfurt am Main Germany

Funder

Janssen Pharmaceuticals

Vertex Pharmaceuticals Incorporated

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12703/fullpdf

Reference33 articles.

1. How to optimize HCV therapy in genotype 1 patients: predictors of response;Petta;Liver Int,2013

2. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy;D'Souza;Am J Gastroenterol,2005

3. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients;Romero-Gómez;Gastroenterology,2005

4. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin;Chu;Aliment Pharmacol Ther,2009

5. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model;Forns;Hepatology,2002

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents;Expert Review of Gastroenterology & Hepatology;2020-11-02

2. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b;Gut and Liver;2018-03-15

3. Changes in serum lipid profiles caused by three regimens of interferon‐free direct‐acting antivirals for patients infected with hepatitis C virus;Hepatology Research;2017-09-22

4. The benefit of statins in chronic hepatitis C patients;European Journal of Gastroenterology & Hepatology;2017-07

5. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients;Journal of Viral Hepatitis;2015-07-27